HTB homepage • Conference reports • Articles by subject • Subscribe 23 February 2018 Contents Editorial 23 February 2018: vol 19 no 4 Conference reports CROI 2018 – highlights from the preliminary programme Antiretrovirals FDA grants tentative approval to first DTG/FTC/TAF FDC Treatment access Universal ART on diagnosis: approved by NHS England Pregnancy Standard once-daily dolutegravir dosing achieves target levels during pregnancy PK and drug interactions Significant drug-drug interaction between dolutegravir and isoniazid-rifapentine Side effects Meta-analysis reports no significant risk of cardiac, IRIS or suicide with dolutegravir Cure-related research New data on identifying and targeting the latent HIV reservoir Recruiting natural killer cells to target HIV persistence Other news Discrimination against gay men overturned with new HPV vaccine programme for England UK study highlights discrimination against trans people living with HIV On the web PrEP resources for access PDFs 23 February 2018: vol 19 no 4 HTB homepage • Conference reports • Articles by subject • Subscribe
